KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Taxes (2019 - 2025)

AbbVie (ABBV) has disclosed Change in Taxes for 7 consecutive years, with $646.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Taxes rose 135.83% to $646.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$762.0 million, a 76.25% increase, with the full-year FY2025 number at -$762.0 million, up 76.25% from a year prior.
  • Change in Taxes was $646.0 million for Q4 2025 at AbbVie, up from -$411.0 million in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $646.0 million in Q4 2025 to a low of -$1.8 billion in Q2 2024.
  • A 5-year average of -$260.3 million and a median of $42.0 million in 2023 define the central range for Change in Taxes.
  • Peak YoY movement for Change in Taxes: tumbled 5892.31% in 2021, then soared 545.45% in 2022.
  • AbbVie's Change in Taxes stood at -$662.0 million in 2021, then skyrocketed by 154.08% to $358.0 million in 2022, then rose by 14.8% to $411.0 million in 2023, then crashed by 538.69% to -$1.8 billion in 2024, then skyrocketed by 135.83% to $646.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Change in Taxes are $646.0 million (Q4 2025), -$411.0 million (Q3 2025), and -$1.4 billion (Q2 2025).